2 completed, 1 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Acumen Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants sabirnetug (ACU193), Sabirnetug + rHuPH20 - Alzheimer Disease | Phase 1 | Completed | Acumen Pharmaceuticals | 28 | 2024-06-25 | 2024-10-18 |
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) sabirnetug, Placebo - Alzheimer Disease | Phase 2 | Active not recruiting | Acumen Pharmaceuticals | 542 | 2024-02-29 | 2025-10-27 |
| A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD ACU193, Placebo - Alzheimer Disease | Phase 1 | Completed | Acumen Pharmaceuticals | 65 | 2021-06-21 | 2023-07-19 |
Alzheimer Disease (3) · Cognitive Dysfunction (2) · Memory Disorders (1)
United States (3) · Canada (1) · Germany (1) · Spain (1) · United Kingdom (1)
Eric Siemers, M.D. (1) · Eric Siemers, MD (1) · Russell Barton (1)
2023 (1), U01AG053247 (1)